Destiny Wealth Partners’s Moderna MRNA Stock Holding History

Destiny Wealth Partners’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-103	Closed	-$5.23K	–	744
2026 Q1	$5.23K	Buy	+103	New	+$4.8K	﹤0.01%	976
2024 Q3	–	Sell	-2,000	Closed	-$238K	–	163
2024 Q2	$238K	Hold	2,000	–	–	0.04%	142
2024 Q1	$213K	Hold	2,000	–	–	0.04%	151
2023 Q4	$217K	Sell	2,000 -10	-0.5%	-$841	0.04%	149
2023 Q3	$208K	Hold	2,010	–	–	0.04%	158
2023 Q2	$254K	Hold	2,010	–	–	0.05%	144
2023 Q1	$309K	Hold	2,010	–	–	0.06%	131
2022 Q4	$361K	Hold	2,010	–	–	0.08%	120
2022 Q3	$238K	Buy	2,010 +2,000	+20,000%	+$303K	0.05%	174
2022 Q2	$1K	Hold	10	–	–	﹤0.01%	588
2022 Q1	$2K	Hold	10	–	–	﹤0.01%	494
2021 Q4	$3K	Hold	10	–	–	﹤0.01%	501
2021 Q3	$4K	Buy	+10	New	+$3.69K	﹤0.01%	471
2021 Q1	–	Sell	-13	Closed	-$1K	–	559
2020 Q4	$1K	Buy	+13	New	+$1.31K	﹤0.01%	499

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Destiny Wealth Partners's MRNA Position: Q2 2026 in Review

Destiny Wealth Partners sold out of Moderna (MRNA) in Q2 2026, closing a stake of 103 shares — an estimated $5.23K sold.

Destiny Wealth Partners first reported a position in MRNA in Q4 2020 and held it in 14 quarters. The position peaked at $361K in Q4 2022. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Destiny Wealth Partners reported no remaining Moderna position as of Q2 2026 after selling out during the quarter.
Destiny Wealth Partners sold 103 Moderna shares in Q2 2026, an estimated $5.23K.
Destiny Wealth Partners first reported a position in Moderna in Q4 2020 and held it in 14 quarters.
Destiny Wealth Partners's Moderna position peaked at $361K in Q4 2022.
782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Destiny Wealth Partners's 13F filing for Q2 2026, filed 7 Aug 2026.